Best Probiotic for IBS in the UK: What the Evidence Shows
Only a handful of probiotic strains and formulations have been tested in people with IBS. This guide covers the ones that have, what UK guidelines advise, how to run a proper 4-week trial, and where CDS22-formula fits.
No single probiotic has been established as the best for irritable bowel syndrome (IBS). The largest meta-analysis, Goodoory et al. (Gastroenterology, 2023, PMID 37541528), pooled 82 randomised trials in 10,332 patients. It found that some strains or combinations may help, but rated the certainty of the evidence low to very low across almost all analyses.
A 2026 strain-specific meta-analysis (Maslennikov et al., J Clin Med, PMID 41682832) reported benefit for strains including Bifidobacterium longum 35624, Lactiplantibacillus plantarum 299v and Lactobacillus rhamnosus GG. Several strains have shown benefit for specific symptoms in placebo-controlled studies, but the reviews do not establish which strain is best.
UK guidelines have not changed. NICE CG61 advises anyone who chooses to try a probiotic to take it for at least 4 weeks at the manufacturer's dose and monitor the effect. The British Society of Gastroenterology (Gut, 2021) names no strain. Probiotics are FSA-regulated food supplements, not medicines. Probiotic.co.uk distributes CDS22-formula. The De Simone Formulation its manufacturer says it contains is one of the few multi-strain formulations tested against placebo in IBS, in five trials published as VSL#3*. It was better than placebo for symptom relief in a multicentre trial in 59 children (Guandalini et al., 2010), and adult trials reported improved symptoms (Wong et al., 2015) and lower flatulence scores (Kim et al., 2005). Results were mixed: Kim et al. (2003) found no significant difference in overall relief.
Irritable bowel syndrome (IBS) definition: IBS is a common long-term condition of the digestive system, now classed by the British Society of Gastroenterology as a disorder of gut-brain interaction, with symptoms such as abdominal pain, bloating and a change in bowel habit.2
There is no proven best probiotic for IBS, and UK guidelines do not name a brand or strain. Several strains have shown benefit for specific symptoms in placebo-controlled studies, but no review establishes which is best. The evidence-based approach is to choose one product whose strain has published IBS evidence, take it daily at the manufacturer's dose for at least 4 weeks, and continue only if your symptoms improve. Probiotics are food supplements regulated by the FSA. They are not medicines and they do not treat IBS. If symptoms are new, severe or changing, see a GP first.
CDS22-formula, from the sole UK and Ireland distributor
- 8 named strains, each with its NCIMB code on the pack.
- 450 billion CFU per sachet, stated on the label.
- Ice pack and insulated liner in every order, dispatched Monday to Thursday.
Food supplement. Not a medicine. The research behind the formulation is set out further down this page.
- Is there one best probiotic for IBS? No. Goodoory 2023 (82 trials, 10,332 patients) rated certainty low to very low
- Strains reported to help specific symptoms: include B. longum 35624, L. plantarum 299v and L. rhamnosus GG (Maslennikov 2026). None is established as best
- NICE CG61: If you choose to try one, take it for at least 4 weeks at the manufacturer's dose and monitor the effect
- British Society of Gastroenterology 2021: Probiotics as a group may help; up to 12 weeks is reasonable (weak recommendation)
- 35624 strain trial: Whorwell 2006, 362 women, benefit over placebo at 4 weeks at one dose
- Multi-strain liquid trial: Sisson 2014, 186 patients, symptom severity score improved over 12 weeks (P = 0.01)
- De Simone Formulation trials: Five placebo-controlled IBS trials (as VSL#3*). Better than placebo for symptom relief in 59 children (Guandalini 2010); improved symptoms in 42 adults (Wong 2015); no overall difference in Kim 2003
- Low FODMAP diet: In a UK trial of 104 people, a multistrain probiotic kept Bifidobacterium levels higher than placebo (Staudacher 2017)
- Safety: No significant increase in adverse events in trials covering more than 7,000 patients (Goodoory 2023)
- Is a probiotic a medicine? No. It is a food supplement and cannot claim to treat IBS
- UK regulatory status: FSA-regulated food supplement, no prescription required
- UK VAT rate on supplements: 20%
- Not a medicine and not a treatment or cure for IBS
- Not proven as a category winner: no strain has been established as best
- Not all tested: only a handful of strains and formulations have IBS trial data
- Not interchangeable: evidence for one strain says nothing about another
- Not a substitute for seeing a GP about new, severe or changing symptoms
Where there is strain-specific evidence: Several strains have shown benefit for specific IBS symptoms in placebo-controlled studies, including Bifidobacterium longum 35624 and Lactiplantibacillus plantarum 299v (Maslennikov et al., J Clin Med, 2026, PMID 41682832; Brindicci et al., Probiotics Antimicrob Proteins, 2026, PMID 43033380). The reviews do not establish which strain is best.
What is not proven: That any one strain is best. Goodoory et al. (Gastroenterology, 2023, PMID 37541528) rated certainty low to very low across almost all analyses, and a 2026 umbrella review of 27 systematic reviews reached the same view.
Most relevant trial length: At least 4 weeks (NICE CG61); up to 12 weeks is reasonable (British Society of Gastroenterology, 2021, weak recommendation).
Key safety note: See a GP before self-managing if symptoms are new, severe or changing. Immunocompromised people should take medical advice before using any live bacteria product.
| Question | Answer | Evidence level |
|---|---|---|
| Do probiotics help IBS as a group? | They may help global symptoms and abdominal pain | BSG 2021: weak recommendation |
| Is one strain best? | Not established. Several strains have shown benefit for specific symptoms | Goodoory 2023; Maslennikov 2026 |
| How long to try one? | At least 4 weeks; up to 12 is reasonable | NICE CG61; BSG 2021 |
| Are they safe? | No significant increase in adverse events | Goodoory 2023 |
| UK regulatory status | Food supplement, not a medicine; 20% VAT | FSA; retained Regulation 1924/2006 |
- What UK guidelines and meta-analyses say
- Best probiotics for IBS UK: the evidence by strain and product
- IBS-D, IBS-C and IBS-M: does the type matter?
- How probiotics might help IBS
- Probiotics and the low FODMAP diet
- How to try a probiotic for IBS: the 4-week test
- Refrigerated or shelf-stable?
- CDS22-formula and IBS: the research behind the formulation
- Probiotics for IBS in the UK: regulation, VAT and prescriptions
- When to see a GP
- Frequently asked questions
What UK guidelines and meta-analyses say about probiotics for IBS
NICE (CG61) does not recommend for or against probiotics. It says that people who choose to try one should take it for at least 4 weeks, at the manufacturer's dose, while monitoring the effect.1 The NHS gives the same practical message: probiotics may help, and you can try them for a month.15
The British Society of Gastroenterology (Vasant et al., Gut, 2021, PMID 33903147) says probiotics as a group may be effective for global symptoms and abdominal pain, but that it is not possible to recommend a specific species or strain. As a weak recommendation, it says a trial of up to 12 weeks is reasonable, stopping if there is no improvement.2
The American Gastroenterological Association (Su et al., Gastroenterology, 2020, PMID 32531291) is more cautious. It recommends probiotics for IBS only in the context of a clinical trial.3
The meta-analyses since then point the same way with more detail. Goodoory et al. (2023) pooled 82 trials in 10,332 patients: some strains or combinations may be beneficial, but certainty was low to very low across almost all analyses.4 Tang et al. (J Gastroenterol Hepatol, 2026, PMID 41820241) found probiotics improved the IBS symptom severity score but not the quality-of-life score, and concluded that more high-powered trials are needed.7 An umbrella review of 27 systematic reviews (Ballena-Caicedo et al., J Clin Med, 2026, PMID 41827145) rated the overall certainty as low.8 An earlier analysis of 53 trials (Ford et al., 2018) had reached a similar conclusion.14
Newer research is starting to separate strains with evidence from strains without. UK guidelines have not moved to recommending a specific strain. They tell you how to test one: a fixed period, a consistent dose, and an honest check on whether anything changed.
Best probiotics for IBS UK: the evidence by strain and product
Evidence belongs to the exact strain or formulation that was tested, at the dose tested. Only a handful have been tested in people with IBS: the 2026 strain-by-strain review covered 10 strains.5 The table shows the ones we checked against the published record. We stock the formulation in the highlighted row. For a wider brand comparison, see our clinical probiotics UK guide.
| What was tested | Evidence | Result against placebo |
|---|---|---|
| De Simone Formulation (studied as VSL#3*). CDS22-formula's manufacturer states it contains this formulation. No trial under the CDS22-formula name. Available from Probiotic.co.uk | Five placebo-controlled trials: Guandalini 2010 (59 children, multicentre), Wong 2015 (42 adults), Kim 2005 (IBS with bloating), Michail 2011 (24 adults, IBS-D), Kim 2003 (25 adults, IBS-D) | Children: better than placebo for symptom relief, pain and bloating (P < 0.05). Adults: improved symptoms (Wong); lower flatulence scores (Kim 2005); improvement in specific symptom scores (Michail); no significant difference in overall relief (Kim 2003) |
| Bifidobacterium longum 35624 (reported as B. infantis 35624 in 2006) | Whorwell 2006: 362 women, 4 weeks. Pooled in Maslennikov 2026 | Benefit at the 1×10⁸ CFU dose; 2026 meta-analysis reports benefit for key symptoms |
| Lactiplantibacillus plantarum 299v (DSM 9843) | Brindicci 2026 meta-analysis: 6 trials, 527 adults | Improved abdominal pain, bloating, flatulence and global symptoms; no significant effect on constipation |
| Lactobacillus rhamnosus GG | Pooled in Maslennikov 2026 | Reported effective for key IBS symptoms |
| Multi-strain liquid | Sisson 2014: 186 patients, 12 weeks | Symptom severity score improved (P = 0.01); no improvement in quality-of-life score |
Other strains have been studied, with negative or conflicting results for some.5 This table covers only evidence we checked against its published record.
Covering 10 strains, it reported that Bifidobacterium longum 35624, Lactobacillus rhamnosus GG and Lactiplantibacillus plantarum 299v were effective for key IBS symptoms. Results for Saccharomyces boulardii CNCM I-745 were conflicting, and Escherichia coli Nissle 1917 showed no efficacy.5
Limitation: few trials per strain; it does not rank strains against each other.
Maslennikov R et al. J Clin Med. 2026;15(3). PMID 41682832.
Significant reductions in abdominal pain, and improvements in bloating, flatulence and global symptoms compared with placebo. No significant effect on constipation.6
Brindicci VF et al. Probiotics Antimicrob Proteins. 2026. PMID 43033380.
A randomised, double-blind, placebo-controlled trial from the University of Manchester. The 1×10⁸ CFU dose produced a significant improvement in the composite IBS symptom score at 4 weeks. The other doses tested did not.10
Limitation: women only, primary care, 4 weeks. A product's current dose may differ from the trial dose.
Whorwell PJ et al. Am J Gastroenterol. 2006;101(7):1581-90. PMID 16863564.
The mean change in IBS symptom severity score was -63.3 with the probiotic and -28.3 with placebo, a difference of -35.0 (95% CI -62.03 to -7.87; P = 0.01). There was no significant improvement in the quality-of-life score, and no serious adverse events.11
Limitation: single centre; 152 of 186 completed.
Sisson G et al. Aliment Pharmacol Ther. 2014;40(1). PMID 24815298.
A multicentre, randomised, double-blind, placebo-controlled crossover trial in children aged 4 to 18, with 6 weeks on each treatment. The probiotic was significantly better than placebo for the primary endpoint, relief of symptoms (P < 0.05), and for abdominal pain, bloating (both P < 0.05) and family life disruption (P < 0.01). Stool pattern did not differ significantly (P = 0.06).18
Limitation: children, not adults; 59 completed.
Guandalini S et al. J Pediatr Gastroenterol Nutr. 2010;51(1):24-30. PMID 20453678.
A randomised, double-blind, placebo-controlled trial. The authors reported that the probiotic improved symptoms and raised rectal pain thresholds, and that symptom improvement tracked a rise in morning melatonin.19
Limitation: small, 6 weeks, designed mainly to study a mechanism.
Wong RK et al. Dig Dis Sci. 2015;60(1):186-94. PMID 25092036.
Patients took 450 billion bacteria a day or placebo for 8 weeks. There were no significant differences in gut transit, bowel function scores or satisfactory global symptom relief. Bloating fell within the probiotic group (P = 0.046), but the difference against placebo was not statistically significant (P = 0.09). There was no effect on pain, gas or urgency.12
Limitation: very small (n = 25).
Kim HJ et al. Aliment Pharmacol Ther. 2003;17(7):895-904. PMID 12656692.
The follow-up trial reported reduced flatulence scores and slower colonic transit with the probiotic, without any change in bowel function.13
Limitation: small trial; flatulence is one symptom, not overall IBS relief.
Kim HJ et al. Neurogastroenterol Motil. 2005;17(5). PMID 16185307.
A double-blind, randomised, placebo-controlled pilot. The authors reported improvement in specific IBS symptom scores, with a favourable change on the satiety subscale in the probiotic group. The gut microbiota did not change.20
Limitation: pilot size (n = 24).
Michail S, Kenche H. Probiotics Antimicrob Proteins. 2011;3(1):1-7. PMID 22247743.
The American Gastroenterological Association recommended that probiotics be used for IBS only in the context of a clinical trial, citing a knowledge gap.3
Su GL et al. Gastroenterology. 2020;159(2). PMID 32531291.
Some combinations or strains may be beneficial in IBS, but certainty in the evidence was low to very low across almost all analyses. None of this evidence applies to people without IBS.4
Goodoory VC et al. Gastroenterology. 2023;165(5). PMID 37541528.
IBS-D, IBS-C and IBS-M: does the type change the choice?
Evidence is increasingly being analysed by IBS subtype, but no UK guideline recommends a specific strain for IBS-D, IBS-C or IBS-M.12
A meta-analysis of 16 trials in 2,823 patients (Almalki et al., Medicina, 2026, PMID 41597375) looked at strains across IBS-C, IBS-D, IBS-M and unclassified IBS. Probiotics reduced discomfort and improved overall symptoms compared with placebo, without more adverse events.9 It does not establish a best strain for any subtype.
| Main issue | Evidence we verified for this guide | Verdict |
|---|---|---|
| IBS-D (diarrhoea) | Almalki 2026 pooled subtype trials. Two small De Simone Formulation trials in IBS-D (Kim 2003, 25 people; Michail 2011, 24 people) were too small to settle it | No proven best choice |
| IBS-C (constipation) | Brindicci 2026: 299v showed no significant effect on constipation | Not established |
| IBS-M (mixed) | No strain-specific result verified for this guide | Not established |
| Bloating | Guandalini 2010: De Simone Formulation improved bloating in children (P < 0.05). Kim 2005: lower flatulence scores in adults. Brindicci 2026: 299v improved bloating. Kim 2003: difference not significant (P = 0.09) | Varies by strain |
If bloating is what bothers you most, our probiotics for bloating UK guide covers that evidence in more depth.
The clinical research discussed in this article relates to probiotics as studied in people with irritable bowel syndrome. It should not be read as a claim that CDS22-formula produces these effects. CDS22-formula is a food supplement, not a medicine. No authorised UK health claim is made for it on this page or on the product.
CDS22-formula: 8 named strains, 450 billion CFU per sachet
A multi-strain live bacteria food supplement with every strain's NCIMB code on the pack.
Probiotic.co.uk · Sole UK and Ireland distributor · Not a medicine · Price includes 20% VAT
How probiotics might help IBS
Nobody has shown exactly how a probiotic could ease IBS symptoms. These are the ideas researchers have tested.
Disturbances in the gut microbiome may be involved in IBS. Probiotics are studied as one way to influence it.
Evidence: proposed — Ford 2018 (PMID 30294792)IBS is now classed as a disorder of gut-brain interaction. Whether probiotics act on this pathway in people is not established.
Evidence: classification — BSG 2021 (PMID 33903147)The 299v meta-analysis reported less bloating and flatulence. Kim 2005 reported lower flatulence scores; in Kim 2003 the bloating difference was not significant.
Evidence: varies by strain — Brindicci 2026; Kim 2003, 2005Kim 2005 reported slower colonic transit. Kim 2003 found no change in transit. The findings do not agree.
Evidence: conflicting small RCTsProbiotics and the low FODMAP diet
The low FODMAP diet is one of the main dietary approaches for IBS in the UK. NICE says the advice should come from a healthcare professional with expertise in dietary management.1 One UK trial tested the diet alongside a probiotic.
A placebo-controlled trial at two UK hospitals. People were randomised to a low FODMAP or sham diet, and to a multistrain probiotic or placebo. The low FODMAP diet reduced symptom scores, but it also lowered Bifidobacterium levels in stool (P = .008). People given the probiotic had higher Bifidobacterium levels than those given placebo (P = .019).22
Limitation: symptom severity scores did not differ between probiotic and placebo (P = .721). The abstract does not name the product. An independent paper lists the eight strains used (Turan et al., 2021, PMID 34616808), and the published bibliography for the De Simone Formulation lists this trial.
Staudacher HM et al. Gastroenterology. 2017;153(4):936-947. PMID 28625832.
This is the trial that looked at what a probiotic adds to the diet. In it, the probiotic group kept higher Bifidobacterium levels while the diet did the work on symptoms. Speak to your dietitian before adding anything to a supervised diet.
How to try a probiotic for IBS: the 4-week test
NICE's advice is short: if you choose to try a probiotic, take it for at least 4 weeks at the manufacturer's dose and monitor the effect.1 The steps below are our practical suggestions for doing that. They are not a NICE protocol.
- One product at a time. Otherwise you cannot tell what did what.
- The manufacturer's dose, every day. This part is NICE's advice.
- Avoid other optional changes if you can. Do not delay or change any prescribed treatment to run this test.
- Keep a simple diary. Score pain, bloating and bowel habit each day.
- Review at 4 weeks. Better: carry on. No change: stop or try a different strain.
Write down your usual symptoms for a few days so you have something to compare against.
Take it daily at the manufacturer's dose. NICE sets 4 weeks as the minimum.1
Compare your diary with your starting notes. The Whorwell 2006 trial measured its result at this point.10
A trial only tells you something if you take it every day. If CDS22-formula is the one you want to test, Subscribe & Save keeps your supply arriving through the trial, or you can order a single box first.
Not sure what counts as a change? See signs probiotics are working.
Refrigerated or shelf-stable: does storage matter?
Some probiotics are made to be kept in the fridge and some are not. Follow the storage instructions on the pack, because the CFU figure on a label assumes the product was stored as directed. Our cold chain guide explains this in full, and our high-strength probiotics guide explains what CFU numbers do and do not tell you.
Packed with an ice pack, dispatched Monday to Thursday
- Ice pack and insulated liner in every box, all year round.
- Dispatched Monday to Thursday so it does not sit in a depot over a weekend.
- Tracked by Royal Mail Tracked 24 or DPD.
"...the probiotics arrive cool in secure packaging."
Jane, Trustpilot, July 2026"The website is clear and easy to use and the delivery is so quick."
Sarah, Trustpilot, September 2026Food supplement. Not a medicine. Reviews describe ordering and delivery, not health outcomes.
CDS22-formula and IBS: the research behind the formulation
Only a handful of probiotic strains and formulations have been through placebo-controlled IBS trials. The De Simone Formulation has been through five.
CDS22-formula is an 8-strain live bacteria food supplement at 450 billion CFU per sachet, with each strain identified on the current UK label by its NCIMB deposit code. Its manufacturer, EOS2021 S.r.l., states that it contains the De Simone Formulation. No clinical trial has been conducted on CDS22-formula under that product name. The current label details are on the product page.
What the IBS trials of that formulation, published as VSL#3*, found:
- Children, multicentre trial: significantly better than placebo for symptom relief, abdominal pain and bloating in 59 children aged 4 to 18 (Guandalini 2010).18
- Adults, 6 weeks: the authors reported improved symptoms and higher rectal pain thresholds in 42 adults (Wong 2015).19
- Adults with bloating: lower flatulence scores than placebo (Kim 2005).13
- Adults with IBS-D: improvement in specific symptom scores in a 24-person pilot (Michail and Kenche 2011).20
- On the low FODMAP diet: higher Bifidobacterium levels than placebo in a 104-person UK trial listed in the formulation's bibliography (Staudacher 2017).22
Not every result was positive. In 25 adults with IBS-D there was no significant difference from placebo in overall relief (Kim 2003), and in the Staudacher trial symptom scores did not differ between probiotic and placebo.1222 That is why the sensible test is your own: 4 weeks, daily, with a diary.
Two open-label pilots without a placebo group also reported fewer symptoms: Ng 2013 (10 patients, improvement in six) and Boonma 2021 (15 people, fewer abdominal pain episodes after 4 and 8 weeks).2123 The full clinical bibliography for the formulation lists every published study.
The formulation's largest body of research is in other areas, which we cover in our guide to the evidence in UC and pouchitis. Those are different conditions, so we keep that evidence separate.
The strain list and NCIMB codes are printed on the pack. The CFU count per sachet is stated. Orders are packed with an ice pack and insulated liner. These are facts about the product, not claims about what it does.
Probiotics for IBS in the UK: regulation, VAT and prescriptions
These products are sold in the UK as food supplements under rules overseen by the Food Standards Agency (FSA).17 They are not medicines licensed by the MHRA, and you do not need a prescription to buy one.
No health claim linking probiotic bacteria to IBS is authorised under retained Regulation (EC) 1924/2006 as it applies in Great Britain. A compliant product cannot say it treats, prevents or cures IBS.
Regulator: Food Standards Agency (FSA) · Medicines regulator: MHRA · Clinical guidance: NICE CG61 and the British Society of Gastroenterology · VAT on supplements: 20% · Prescription needed: No
When to see a GP
IBS should be diagnosed by a GP, not assumed. The NHS advises seeing a GP if you think you might have IBS and your symptoms have lasted more than 4 weeks.16 Do not start a supplement in place of getting symptoms checked.
Lost a lot of weight for no clear reason, bleeding from your bottom or bloody diarrhoea, a hard lump or swelling in your tummy, or shortness of breath, noticeable heartbeats and skin that is paler than usual. This is the NHS list.16 Stop any probiotic and seek advice if your symptoms get worse.
The clinical research discussed in this article relates to probiotics as studied in people with irritable bowel syndrome. It should not be read as a claim that CDS22-formula produces these effects. CDS22-formula is a food supplement, not a medicine. No authorised UK health claim is made for it on this page or on the product.
CDS22-formula from Probiotic.co.uk
8 strains · 450 billion CFU per sachet · Dispatched with an ice pack and insulated liner.
Probiotic.co.uk · Sole UK and Ireland distributor · Easi-Chill packs + foil liner · Not a medicine · Price includes 20% VAT · Mon–Thu dispatch
CDS22-formula product details on this page (8 NCIMB-coded strains; sachets at 450 billion CFU, 12 per box; capsules at 112 billion CFU, 20 per pack) were checked against the live Probiotic.co.uk listings on 18 November 2026. Prices change, so the current price is shown on the product page. Always check the label before use.
Frequently asked questions
What is the best probiotic for IBS in the UK?
No single probiotic has been established as the best for IBS, and UK guidelines do not recommend a specific strain. The largest meta-analysis (Goodoory et al., Gastroenterology, 2023, PMID 37541528) pooled 82 trials in 10,332 patients and rated the certainty of the evidence low to very low for almost all analyses. A 2026 strain-specific meta-analysis (Maslennikov et al., J Clin Med, PMID 41682832) reported benefit for strains including Bifidobacterium longum 35624, Lactiplantibacillus plantarum 299v and Lactobacillus rhamnosus GG, but the reviews do not establish which strain is best.
What does NICE say about probiotics for IBS?
NICE clinical guideline CG61 advises that people with IBS who choose to try probiotics should take the product for at least 4 weeks, at the dose the manufacturer recommends, while monitoring the effect on their symptoms. NICE does not name a brand or strain. The NHS gives similar advice, suggesting probiotics may help and can be tried for a month.
How long should I try a probiotic for IBS?
At least 4 weeks, according to NICE CG61. The British Society of Gastroenterology guideline (Gut, 2021, PMID 33903147) says, as a weak recommendation, that it is reasonable to try a probiotic for up to 12 weeks and to stop if symptoms have not improved. Do not delay or change any prescribed treatment in order to test a supplement.
Which probiotic is best for IBS with diarrhoea (IBS-D)?
No probiotic has been established as best for IBS-D, and UK guidelines do not recommend different strains for different IBS types. A meta-analysis of 16 trials in 2,823 patients (Almalki et al., Medicina, 2026, PMID 41597375) analysed strains across IBS subtypes and found probiotics improved overall symptoms compared with placebo. Small IBS-D trials exist for several products, including the De Simone Formulation (Kim et al., 2003, 25 patients; Michail and Kenche, 2011, 24 patients), but none is large enough to settle the question.
Which probiotic is best for IBS with constipation (IBS-C)?
No probiotic has been established as best for IBS-C. A 2026 meta-analysis of Lactiplantibacillus plantarum 299v (Brindicci et al., Probiotics Antimicrob Proteins, PMID 43033380) found improvements in abdominal pain, bloating and global symptoms but no significant effect on constipation. If constipation is your main symptom, speak to a GP or pharmacist about first-line options before relying on a supplement.
Is a multi-strain probiotic better than a single strain for IBS?
It has not been shown either way. Single strains with meta-analytic support in 2026 include Bifidobacterium longum 35624 and Lactiplantibacillus plantarum 299v (Maslennikov et al., PMID 41682832; Brindicci et al., PMID 43033380). Multi-strain products with placebo-controlled IBS trials include the De Simone Formulation (Guandalini et al., 2010, PMID 20453678) and a multi-strain liquid (Sisson et al., 2014, PMID 24815298). What matters is whether the exact strain or formulation has been tested in people with IBS.
Are probiotics safe for people with IBS?
In the Goodoory et al. 2023 meta-analysis (PMID 37541528), there was no significant increase in adverse events with probiotics in trials covering more than 7,000 patients. A 2026 umbrella review of 27 systematic reviews (Ballena-Caicedo et al., PMID 41827145) also found adverse events in line with placebo. People who are immunocompromised, seriously ill or under specialist care should speak to their GP before taking any live bacteria product.
Has CDS22-formula been tested in IBS?
No clinical trial has been conducted on CDS22-formula under that product name. Its manufacturer, EOS2021 S.r.l., states that it contains the De Simone Formulation, which was studied in five placebo-controlled IBS trials published as VSL#3*. In a multicentre trial in 59 children it was significantly better than placebo for symptom relief, abdominal pain and bloating (Guandalini et al., 2010, PMID 20453678). In adults, Wong et al. (2015, PMID 25092036) reported improved symptoms and Kim et al. (2005, PMID 16185307) reported lower flatulence scores, while Kim et al. (2003, PMID 12656692) found no significant difference in overall relief. CDS22-formula is a food supplement, not a medicine.
Can you take a probiotic on the low FODMAP diet?
One UK trial tested the two together. Staudacher et al. (Gastroenterology, 2017, PMID 28625832) randomised 104 people with IBS at two UK hospitals to a low FODMAP or sham diet, plus a multistrain probiotic or placebo, for 4 weeks. The low FODMAP diet lowered Bifidobacterium levels in stool, while people given the probiotic had higher Bifidobacterium levels than those given placebo (P = .019). Symptom severity scores did not differ between probiotic and placebo. NICE CG61 says low FODMAP advice should come from a healthcare professional with expertise in dietary management.
Are probiotics for IBS legal in the UK and do they need a prescription?
Yes, they are legal in the UK and no prescription is needed. They are sold as food supplements under rules overseen by the Food Standards Agency (FSA), not as medicines licensed by the MHRA. No health claim for probiotic bacteria and IBS is authorised under retained Regulation (EC) 1924/2006, so compliant products cannot claim to treat IBS. UK VAT on food supplements is 20%.
Where can I buy CDS22-formula in the UK?
CDS22-formula is available from Probiotic.co.uk as sachets (450 billion CFU per sachet, 12 per box) and capsules (112 billion CFU per capsule, 20 per pack). Orders are packed with an ice pack and insulated liner and dispatched Monday to Thursday by Royal Mail Tracked 24 or DPD. See the product page for the current price. Not a medicine.
- No single probiotic has been established as the best for irritable bowel syndrome.
- A probiotic is a food supplement, not a medicine, and cannot claim to treat IBS.
- NICE CG61 advises that people who choose to try a probiotic take it for at least 4 weeks at the manufacturer's dose while monitoring the effect.
- The British Society of Gastroenterology (Gut, 2021, PMID 33903147) says probiotics as a group may help and that up to 12 weeks is a reasonable trial (weak recommendation).
- Goodoory et al. (Gastroenterology, 2023, PMID 37541528) pooled 82 trials in 10,332 patients and rated certainty low to very low across almost all analyses.
- Maslennikov et al. (J Clin Med, 2026, PMID 41682832) reported benefit for strains including Bifidobacterium longum 35624, Lactiplantibacillus plantarum 299v and Lactobacillus rhamnosus GG.
- Brindicci et al. (2026, PMID 43033380) pooled 6 trials of L. plantarum 299v in 527 adults: pain, bloating and global symptoms improved; constipation did not.
- Sisson et al. (2014, PMID 24815298) reported improved symptom severity with a multi-strain liquid over 12 weeks (P = 0.01).
- The De Simone Formulation has five placebo-controlled IBS trials published as VSL#3*: better than placebo for symptom relief in 59 children (Guandalini 2010, PMID 20453678), improved symptoms in 42 adults (Wong 2015, PMID 25092036), and no significant overall difference in Kim 2003.
- In a UK trial of 104 people with IBS (Staudacher 2017, PMID 28625832), a multistrain probiotic kept Bifidobacterium levels higher than placebo during the low FODMAP diet; symptom scores did not differ.
- In the UK, these products are FSA-regulated food supplements with 20% VAT. No prescription is required.
- CDS22-formula (8 NCIMB strains, 450 billion CFU per sachet) is distributed in the UK by Probiotic.co.uk and dispatched with an ice pack and insulated liner.
Related articles
This guide was prepared by Probiotic.co.uk, which distributes one of the products discussed. The process:
- Read the NICE CG61 recommendations and the NHS IBS pages directly.
- Reviewed the British Society of Gastroenterology 2021 and AGA 2020 guidelines, and meta-analyses from 2018, 2023 and 2026.
- Checked the PubMed record of each trial and review cited. Whorwell 2006 was checked in an earlier review; the rest on 18 November 2026.
- Checked the IBS entries in the published clinical bibliography for the De Simone Formulation against their PubMed records.
- Included strains we do not sell, and reported negative and non-significant results as published.
- Separated what each trial tested from what is sold today.
- Checked CDS22-formula details against the live listings and made no disease-treatment claim for it.
- This guide has not been reviewed by a clinician.
Sources
- National Institute for Health and Care Excellence. Irritable bowel syndrome in adults: diagnosis and management. Clinical guideline CG61. — nice.org.uk/guidance/cg61
- Vasant DH et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7). PMID 33903147. DOI: 10.1136/gutjnl-2021-324598 — pubmed.ncbi.nlm.nih.gov/33903147
- Su GL et al. AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology. 2020;159(2). PMID 32531291. DOI: 10.1053/j.gastro.2020.05.059 — pubmed.ncbi.nlm.nih.gov/32531291
- Goodoory VC et al. Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. Gastroenterology. 2023;165(5). PMID 37541528. DOI: 10.1053/j.gastro.2023.07.018 — pubmed.ncbi.nlm.nih.gov/37541528
- Maslennikov R et al. Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome. J Clin Med. 2026;15(3). PMID 41682832. DOI: 10.3390/jcm15031152 — pubmed.ncbi.nlm.nih.gov/41682832
- Brindicci VF et al. The Effects of Lactiplantibacillus plantarum 299v on Irritable Bowel Syndrome: A Systematic Review with Meta-analysis. Probiotics Antimicrob Proteins. 2026. PMID 43033380. DOI: 10.1007/s12602-026-11296-0 — pubmed.ncbi.nlm.nih.gov/43033380
- Tang ASP et al. Probiotics for Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis With Trial Sequential Analysis. J Gastroenterol Hepatol. 2026;41(4). PMID 41820241. DOI: 10.1111/jgh.70322 — pubmed.ncbi.nlm.nih.gov/41820241
- Ballena-Caicedo J et al. Probiotics in Irritable Bowel Syndrome: An Umbrella Review of 27 Systematic Reviews on Methodological Quality and Certainty of Evidence. J Clin Med. 2026;15(5). PMID 41827145. DOI: 10.3390/jcm15051727 — pubmed.ncbi.nlm.nih.gov/41827145
- Almalki AS et al. Efficacy of Specific Probiotic Strains in Subtypes of Irritable Bowel Syndrome: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicina (Kaunas). 2026;62(1). PMID 41597375. DOI: 10.3390/medicina62010089 — pubmed.ncbi.nlm.nih.gov/41597375
- Whorwell PJ et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101(7):1581-90. PMID 16863564. DOI: 10.1111/j.1572-0241.2006.00734.x — pubmed.ncbi.nlm.nih.gov/16863564
- Sisson G et al. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome, a 12 week double-blind study. Aliment Pharmacol Ther. 2014;40(1). PMID 24815298. DOI: 10.1111/apt.12787 — pubmed.ncbi.nlm.nih.gov/24815298
- Kim HJ et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17(7):895-904. PMID 12656692. DOI: 10.1046/j.1365-2036.2003.01543.x — pubmed.ncbi.nlm.nih.gov/12656692
- Kim HJ et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005;17(5). PMID 16185307. DOI: 10.1111/j.1365-2982.2005.00695.x — pubmed.ncbi.nlm.nih.gov/16185307
- Ford AC et al. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(10). PMID 30294792. DOI: 10.1111/apt.15001 — pubmed.ncbi.nlm.nih.gov/30294792
- NHS. Irritable bowel syndrome (IBS): diet, lifestyle and medicines. — nhs.uk/conditions/irritable-bowel-syndrome-ibs/diet-lifestyle-and-medicines
- NHS. Irritable bowel syndrome (IBS): symptoms. — nhs.uk/conditions/irritable-bowel-syndrome-ibs/symptoms
- UK Food Standards Agency. Food supplements guidance. — food.gov.uk/business-guidance/food-supplements
- Guandalini S et al. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr. 2010;51(1):24-30. PMID 20453678. DOI: 10.1097/MPG.0b013e3181ca4d95 — pubmed.ncbi.nlm.nih.gov/20453678
- Wong RK et al. Melatonin regulation as a possible mechanism for probiotic (VSL#3) in irritable bowel syndrome: a randomized double-blinded placebo study. Dig Dis Sci. 2015;60(1):186-94. PMID 25092036. DOI: 10.1007/s10620-014-3299-8 — pubmed.ncbi.nlm.nih.gov/25092036
- Michail S, Kenche H. Gut microbiota is not modified by Randomized, Double-blind, Placebo-controlled Trial of VSL#3 in Diarrhea-predominant Irritable Bowel Syndrome. Probiotics Antimicrob Proteins. 2011;3(1):1-7. PMID 22247743. DOI: 10.1007/s12602-010-9059-y — pubmed.ncbi.nlm.nih.gov/22247743
- Ng SC et al. Effect of probiotic bacteria on the intestinal microbiota in irritable bowel syndrome. J Gastroenterol Hepatol. 2013;28(10):1624-31. PMID 23800182. DOI: 10.1111/jgh.12306 — pubmed.ncbi.nlm.nih.gov/23800182
- Staudacher HM et al. A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial. Gastroenterology. 2017;153(4):936-947. PMID 28625832. DOI: 10.1053/j.gastro.2017.06.010 — pubmed.ncbi.nlm.nih.gov/28625832
- Boonma P et al. Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Symptoms in Patients With Irritable Bowel Syndrome. Front Pain Res (Lausanne). 2021;2:691689. PMID 35295488. DOI: 10.3389/fpain.2021.691689 — pubmed.ncbi.nlm.nih.gov/35295488